our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD52 (CD52 Molecule)

News alerts, weekly reports and conference planners

29d

CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy. (PubMed, NPJ Breast Cancer)

Additionally, cotreatment with anti-CD52 sensitized tumor cells to PD-1 blockade therapy in the spontaneous MMTV-PyMT TNBC model. Our findings identify CD52 as a prominently expressed anti-phagocytic checkpoint in TNBC and reveal the therapeutic potential of dual PD-1/CD52 blockade as a novel immunotherapeutic strategy.

29 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD52 (CD52 Molecule)

CD52 expression

29d

Single cell transcriptomics derived combinatorial markers distinguished leukemic stem cells from hematopoietic stem cells in acute myeloid leukemia. (PubMed, Leuk Res)

Incorporating these markers in combination with established aberrant markers can enhance the identification of LSCs and help distinguish them from HSCs in both CD34 + and CD34- AML. Our findings support the use of an expanded combinatorial marker panel and warrants its further evaluation in a larger AML cohort, particularly in the context of measurable residual disease (MRD) assessment, prognostication and correlation with treatment response and survival outcomes.

29 days ago

Journal • IO biomarker

CD38 (CD38 Molecule) • CD34 (CD34 molecule) • CD52 (CD52 Molecule) • CD48 (CD48 Molecule) • CD96 (CD96 Molecule)

CiFGNA: Comprehensive information-based functional gene network analysis. (PubMed, Stat Methods Med Res)

Key findings revealed gene networks centered on CD52, EPCAM, and TNFRSF12A as markers of drug-response phenotypes, suggesting that targeting resistance-related molecular interactions (e.g. CD52 and EPCAM) or enhancing sensitivity-associated markers such as TNFRSF12A may improve chemotherapy efficacy. Overall, CiFGNA offers a powerful, generalizable tool for interpreting complex gene networks and advancing systems-level understanding of disease mechanisms.

1 month ago

Journal

EPCAM (Epithelial cell adhesion molecule) • CD52 (CD52 Molecule) • TNFRSF12A (TNF Receptor Superfamily Member 12A)

2ms

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)

Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.

2 months ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)

lenalidomide • bortezomib • cyclophosphamide

3ms

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia. (PubMed, N Engl J Med)

Universal BE-CAR7 T cells induced leukemic remission in patients with relapsed or refractory T-cell ALL, thus allowing successful allogeneic hematopoietic stem-cell transplantation in most of the patients. (Funded by the Medical Research Council and others; ISRCTN Registry number, ISRCTN15323014.).

3 months ago

Journal

CD52 (CD52 Molecule)

cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • BE CAR7 T

3ms

Integration of Transcriptome Profiling and Single-Cell Sequencing Analysis to Establish a CD8+ T Cell-Related Prognostic Model for Patients With NSCLC: From Assessment to Therapy. (PubMed, Cancer Med)

This study constructed an innovative CD8+ T cell-related risk model, advancing clinical diagnosis and offering valuable therapeutic strategies for patients with NSCLC.

3 months ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • CD52 (CD52 Molecule) • PLIN2 (Perilipin)

paclitaxel

4ms

Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer. (PubMed, Discov Oncol)

High expression of NUF2 and CD52 is closely linked to platinum resistance and aggressive tumor behavior in NSCLC, and serves as an independent predictor of adverse outcomes. These markers may hold potential as prognostic indicators and therapeutic targets in chemoresistant NSCLC. These findings, while promising, are based on a single-center retrospective cohort and should be validated in larger, independent studies to confirm their clinical utility.

4 months ago

Journal

CD52 (CD52 Molecule)

CD52 expression

cisplatin • gemcitabine

4ms

Exploring CD19-targeted Immunotherapy Strategies for Human B-cell Lymphoma. (PubMed, Arch Razi Inst)

There are several FDA-approved anti-CD19 CAR-T cells, including Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel, as well as anti-CD19 monoclonal antibodies (mABs), such as loncastuximab tesirine and tafasitamab...Blinatumomab, the inaugural FDA-approved antibody to be produced using BiTE technology, has demonstrated notable benefits in clinical trials investigating its use in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)...Furthermore, we engaged in a discourse on the various treatment options concerning CD19 targeting, accompanied by an exposition of the pertinent clinical studies. In this regard, the efficacy, safety, and limitations of each option were thoroughly delineated.

4 months ago

Review • Journal

CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD52 (CD52 Molecule)

Blincyto (blinatumomab) • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Zynlonta (loncastuximab tesirine-lpyl) • Monjuvi (tafasitamab-cxix)

4ms

Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. (PubMed, Oncol Res)

Although trials for solid tumors (e.g., CYAD-101, CTX130) show modest responses, challenges such as tumor heterogeneity and T cell exhaustion remain. Future research should focus on optimizing gene editing precision, integrating combination therapies, and advancing scalable manufacturing platforms. With expanded targets and cell types, UCAR therapies show promise for both hematologic and solid tumors, reshaping cancer treatment and patient outcomes.

4 months ago

Review • Journal

CD52 (CD52 Molecule)

CYAD-101 • CTX130

4ms

Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma. (PubMed, Gynecol Oncol)

Successful NACT was associated with a reduction in CD52 + KIT+ mast cells and an increase in the JUN+/TNFRSF12A+ subpopulation. The increased infiltration of KIT-expressing mast cells may serve as a prognostic biomarker for HGSC following NACT and represent a potential novel therapeutic target to enhance NACT efficacy.

4 months ago

Journal

KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CD52 (CD52 Molecule) • TNFRSF12A (TNF Receptor Superfamily Member 12A)

KIT expression

5ms

Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1. (PubMed, Leuk Res)

5-Azacitidine (5-Aza) is a hypomethylating agent with demonstrated therapeutic efficacy for myeloid leukemia...The results revealed that two genes (HDC and MICALL2) with increased expression in leukemia cells after 5-Aza treatment were associated with better overall survival, while six genes (BTG2, CD52, PECAM1, PIK3IP1, PTGS2, and TREML2) correlated with worse overall survival. This study revealed that the epigenetic regulation by DNA demethylation in intron 1 has an important role of 5-Aza treatment in myeloid leukemia cells, and suggests novel targets for the development of combination therapy with 5-Aza.

5 months ago

Journal

PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CD52 (CD52 Molecule) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • BTG2 (BTG Anti-Proliferation Factor 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

azacitidine

6ms

Regulation of Tetraspanin CD63 in Chronic Myeloid Leukemia (CML): Single-Cell Analysis of Asymmetric Hematopoietic Stem Cell Division Genes. (PubMed, Bioengineering (Basel))

The single-cell trajectory reconstitution analysis in CP samples showed CD63 regulation highlighting a trajectory cluster implicating HSPB1, PIM2, ANXA5, LAMTOR1, CFL1, CD52, RAD52, MEIS1, and PDIA3, known to be implicated in hematopoietic malignancies. (4) Regulation of CD63, a tetraspanin involved in the asymmetric division of hematopoietic stem cells, was found to be associated with poor prognosis during CML progression and could be a potential new therapeutic target.

6 months ago

Journal

MEIS1 (Meis Homeobox 1) • CD52 (CD52 Molecule) • RAD52 (RAD52 Homolog DNA Repair Protein) • HSPB1 (Heat shock 27kDa protein 1) • PDIA3 (Protein Disulfide Isomerase Family A Member 3) • ANXA5 (Annexin A5) • LAMP2 (Lysosomal Associated Membrane Protein 2)